Platinum Compounds: Difference between revisions
No edit summary |
(Updated category= to treatment_category= in TreatmentInfo template) |
||
| (One intermediate revision by one other user not shown) | |||
| Line 1: | Line 1: | ||
{{TreatmentInfo | {{TreatmentInfo | ||
|drug_name=Platinum Compounds | |drug_name=Platinum Compounds | ||
|FDA_approval=Yes | |FDA_approval=Yes | ||
|used_for=Glioblastoma | |used_for=Glioblastoma | ||
| Line 8: | Line 8: | ||
|usefulness_rating=3 | |usefulness_rating=3 | ||
|notes=Combining Temodar with cisplatin has shown improved PFS-6 in recurrent tumors. A protocol combining Temodar, cisplatin, and etoposide reported median survival of 25 months. | |notes=Combining Temodar with cisplatin has shown improved PFS-6 in recurrent tumors. A protocol combining Temodar, cisplatin, and etoposide reported median survival of 25 months. | ||
| | |treatment_category=Other Chemotherapy and Cancer Drugs | ||
|toxicity_level=4 | |toxicity_level=4 | ||
|toxicity_explanation=The treatment with Platinum Compounds (Cisplatin) is considered relatively high in toxicity due to potential side effects like kidney damage (Nephrotoxicity), hearing loss (ototoxicity), and nervous system damage (neurotoxicity). It's important for patients to discuss these risks with their healthcare provider before starting therapy. A toxicity level of 4 out of 5 means this treatment carries significant risks, but it may be necessary for managing glioblastoma. | |toxicity_explanation=The treatment with Platinum Compounds (Cisplatin) is considered relatively high in toxicity due to potential side effects like kidney damage (Nephrotoxicity), hearing loss (ototoxicity), and nervous system damage (neurotoxicity). It's important for patients to discuss these risks with their healthcare provider before starting therapy. A toxicity level of 4 out of 5 means this treatment carries significant risks, but it may be necessary for managing glioblastoma. | ||
|book_text=An improvement in results relative to those obtained with Temodar alone has also been | |||
reported when Temodar has been combined with cisplatin. In a pair of clinical studies | |||
performed in Italy (61, 62) with patients with recurrent tumors, the PFS-6 was 34% and | |||
35%. A treatment protocol with newly diagnosed patients that also seems to have | |||
produced better results than Temodar as a single agent combined Temodar with both | |||
cisplatin and etoposide (VP-16), given through the carotid artery (63). Cisplatin and | |||
etoposide were given after surgery and continued for three cycles spaced every 3 weeks | |||
apart, followed by the standard protocol of radiation plus low-dose Temodar, then | |||
high-dose Temodar on the schedule of days 1-5 of every month. For 15 patients studied, | |||
median survival was 25 months. | |||
}} | }} | ||
Latest revision as of 10:34, 12 November 2024
| Property | Information |
|---|---|
| Drug Name | Platinum Compounds |
| FDA Approval | Yes |
| Used for | Glioblastoma |
| Clinical Trial Phase | Various, including Phase II |
| Clinical Trial Explanation | Not specified |
| Common Side Effects | Nephrotoxicity, ototoxicity, and neurotoxicity |
| OS without | Not specified |
| OS with | Not specified |
| PFS without | Not specified |
| PFS with | Not specified |
| Usefulness Rating | 3 |
| Usefulness Explanation | Not specified |
| Toxicity Level | 4 |
| Toxicity Explanation | The treatment with Platinum Compounds (Cisplatin) is considered relatively high in toxicity due to potential side effects like kidney damage (Nephrotoxicity), hearing loss (ototoxicity), and nervous system damage (neurotoxicity). It's important for patients to discuss these risks with their healthcare provider before starting therapy. A toxicity level of 4 out of 5 means this treatment carries significant risks, but it may be necessary for managing glioblastoma. |
Notes: Combining Temodar with cisplatin has shown improved PFS-6 in recurrent tumors. A protocol combining Temodar, cisplatin, and etoposide reported median survival of 25 months.
From Ben Williams Book: An improvement in results relative to those obtained with Temodar alone has also been reported when Temodar has been combined with cisplatin. In a pair of clinical studies performed in Italy (61, 62) with patients with recurrent tumors, the PFS-6 was 34% and 35%. A treatment protocol with newly diagnosed patients that also seems to have produced better results than Temodar as a single agent combined Temodar with both cisplatin and etoposide (VP-16), given through the carotid artery (63). Cisplatin and etoposide were given after surgery and continued for three cycles spaced every 3 weeks apart, followed by the standard protocol of radiation plus low-dose Temodar, then high-dose Temodar on the schedule of days 1-5 of every month. For 15 patients studied, median survival was 25 months.Property "Has original text" (as page type) with input value "An improvement in results relative to those obtained with Temodar alone has also been</br>reported when Temodar has been combined with cisplatin. In a pair of clinical studies</br>performed in Italy (61, 62) with patients with recurrent tumors, the PFS-6 was 34% and</br>35%. A treatment protocol with newly diagnosed patients that also seems to have</br>produced better results than Temodar as a single agent combined Temodar with both</br>cisplatin and etoposide (VP-16), given through the carotid artery (63). Cisplatin and</br>etoposide were given after surgery and continued for three cycles spaced every 3 weeks</br>apart, followed by the standard protocol of radiation plus low-dose Temodar, then</br>high-dose Temodar on the schedule of days 1-5 of every month. For 15 patients studied,</br>median survival was 25 months." contains invalid characters or is incomplete and therefore can cause unexpected results during a query or annotation process.
